stockrowARS Pharmaceuticals, Inc.
SPRY Healthcare Biotechnology
ARS Pharmaceuticals, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $84.3 million, down 5.46% from fiscal 2024.
- Revenue
- +16.0%
- EPS
- +30.8%
- Free cash flow
- +36.5%
- Total debt
- +138.5%
Quarter to September 2026, against a year earlier
Follow SPRY
Alert me
ARS Pharmaceuticals, Inc. (SPRY) EV/Sales
As of 6 November 2026, ARS Pharmaceuticals, Inc. (SPRY) trades at a EV/Sales of 2.6×. Over the past ten years it has ranged from −11.5× (January 2023) to 1,827× (March 2024); the current reading is higher than 36% of that period. That is below the Biotechnology industry median of 9.0× and below the Healthcare sector median of 3.6×.
EV/Sales, daily
Embed this chart
Annual newest first
| Period | EV/Sales | Change |
|---|---|---|
| FY2025 | 12.7× | 45.71% |
| FY2024 | 8.7× | (98.83%) |
| FY2023 | 744× | 1,580.91% |
| FY2022 | 44.3× | — |
| FY2021 | 0.0× | — |
Quarterly newest first
| Period | EV/Sales | Change |
|---|---|---|
| Sep 2026 | 3.8× | (46.15%) |
| Jun 2026 | 7.0× | (9.21%) |
| Mar 2026 | 7.8× | (39.02%) |
| Dec 2025 | 12.7× | 107.95% |
| 12 more quarters | Free account |
Against its own ten years
EV/Sales against peers
| Company | EV/Sales |
|---|---|
| QTTB Q32 Bio Inc. compare | −13.6× |
| TTRX Turn Therapeutics Inc. compare | n/m |
| VOGX Vogenx Inc compare | n/m |
| NAUT Nautilus Biotechnology, Inc. compare | n/m |
| RCKT Rocket Pharmaceuticals, Inc. compare | n/m |
| IPSC Century Therapeutics, Inc. compare | 2.0× |
| SPRY ARS Pharmaceuticals, Inc. | 2.6× |
| ARCT Arcturus Therapeutics Holdings Inc. compare | 6.0× |
| SABS SAB Biotherapeutics, Inc. compare | 85.8× |
| Biotechnology industry median | 9.0× |
| Healthcare sector median | 3.6× |
| Market median | 2.1× |
What EV/Sales is
EV/Sales tells an investor how the value of a whole company, counting its debt and cash, compares with the sales it brings in.
((Stock Price × Shares (Basic, Weighted) (latest quarter)) + (Long Term Debt (Total) (latest quarter) + Current Part of Debt (latest quarter)) − Cash & Short Term Investments (latest quarter)) ÷ Revenue (TTM)